Skip to main content

The value of delayed phase enhanced imaging in malignant pleural mesothelioma.

Publication ,  Journal Article
Patel, AM; Berger, I; Wileyto, EP; Khalid, U; Torigian, DA; Nachiappan, AC; Barbosa, EM; Gefter, WB; Galperin-Aizenberg, M; Gupta, NK; Haas, AR ...
Published in: Journal of thoracic disease
August 2017

Cross-sectional imaging of malignant pleural mesothelioma (MPM) can underestimate the presence of local tumor invasion. Since accurate staging is vital optimal choice of therapy, techniques that optimize pleural imaging are needed. Here we estimate the optimal timing of MPM enhancement on magnetic resonance imaging (MRI).All MPM patients with intravenous (IV) contrast enhanced staging MRI between 2000-2016 at our institution were retrospectively selected for image analysis. Patients with incomplete imaging protocol and maximum pleural tumor thickness <1 cm were excluded. Quantitative measurements of tumor signal intensity were obtained on pre-contrast and post-contrast phases where MRI acquisition parameters were fixed. Using best-fit model curves, predicted maximum time points of enhancement were determined using a simulation of predicted values. Additionally, a qualitative assessment of tumor conspicuity was performed at all IV contrast time delays imaged. A statistical analysis assessed for correlation between qualitative lesion conspicuity and quantitative tumor enhancement.Of the 42 MPM patients who had undergone staging MRI during the study period, 12 patients met the study criteria. Peak tumor enhancement was between 150 and 300 sec following IV contrast administration. Within this time window, 80% of patients are projected to have reached >80%, >85%, and >90% peak tumor enhancement. There was a statistically significant correlation between increasing tumor enhancement and subjective lesion conspicuity.Optimal MPM enhancement on MRI likely occurs at a time delay between 2.5-5 min following IV contrast administration. Further study of delayed phase enhancement of MPM with dynamic contrast enhanced MRI is warranted.

Duke Scholars

Published In

Journal of thoracic disease

DOI

EISSN

2077-6624

ISSN

2072-1439

Publication Date

August 2017

Volume

9

Issue

8

Start / End Page

2344 / 2349

Related Subject Headings

  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patel, A. M., Berger, I., Wileyto, E. P., Khalid, U., Torigian, D. A., Nachiappan, A. C., … Katz, S. I. (2017). The value of delayed phase enhanced imaging in malignant pleural mesothelioma. Journal of Thoracic Disease, 9(8), 2344–2349. https://doi.org/10.21037/jtd.2017.07.86
Patel, Akash M., Ian Berger, E Paul Wileyto, Urooj Khalid, Drew A. Torigian, Arun C. Nachiappan, Eduardo M. Barbosa, et al. “The value of delayed phase enhanced imaging in malignant pleural mesothelioma.Journal of Thoracic Disease 9, no. 8 (August 2017): 2344–49. https://doi.org/10.21037/jtd.2017.07.86.
Patel AM, Berger I, Wileyto EP, Khalid U, Torigian DA, Nachiappan AC, et al. The value of delayed phase enhanced imaging in malignant pleural mesothelioma. Journal of thoracic disease. 2017 Aug;9(8):2344–9.
Patel, Akash M., et al. “The value of delayed phase enhanced imaging in malignant pleural mesothelioma.Journal of Thoracic Disease, vol. 9, no. 8, Aug. 2017, pp. 2344–49. Epmc, doi:10.21037/jtd.2017.07.86.
Patel AM, Berger I, Wileyto EP, Khalid U, Torigian DA, Nachiappan AC, Barbosa EM, Gefter WB, Galperin-Aizenberg M, Gupta NK, Simone CB, Haas AR, Alley EW, Singhal S, Cengel KA, Katz SI. The value of delayed phase enhanced imaging in malignant pleural mesothelioma. Journal of thoracic disease. 2017 Aug;9(8):2344–2349.

Published In

Journal of thoracic disease

DOI

EISSN

2077-6624

ISSN

2072-1439

Publication Date

August 2017

Volume

9

Issue

8

Start / End Page

2344 / 2349

Related Subject Headings

  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences